Danaher Buys Beckman: Fixing Quality Issues, Cutting Costs Are Priorities
This article was originally published in The Gray Sheet
Executive Summary
Danaher’s priorities for its newly acquired Beckman Coulter diagnostics business will include cutting $250 million in costs, completing quality control fixes already underway and getting certain cardiac troponin assays back on the market.